Search

Displaying results 6851 - 6860 of 8194 in total
  1. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an

  2. Drug

    SNS01-T

    go.drugbank.com/drugs/DB17302
    Investigational

    It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.

  3. Drug

    Pemlimogene merolisbac

    go.drugbank.com/drugs/DB16286
    Investigational

    Pemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab

  4. Drug

    Lutetium (177Lu) NeoB

    go.drugbank.com/drugs/DB30389
    Investigational

    Lutetium (177Lu) NeoB is under investigation in clinical trial NCT06379217 (NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine

    Synonyms: Lu-NeoB, [177Lu]Lu-NeoB
  5. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  6. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach.

  7. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  8. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it rece...

  9. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.

  10. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    [A263501,L50411] Danicopan is a small molecule complement factor D inhibitor that selectively blocks the alternative pathway, thereby working to address extravascular hemolysis when used in conjunction

    Categories: P-glycoprotein inhibitors, Complement Factor D Inhibitor